Burning Mouth SyndromeEarly Phase 1NCT04481841
Head Yuanshi Dian Therapy in Burning Mouth Syndrome
A Early Phase 1 study testing oryzanol + vitamin B2 (riboflavin) + vitamin E in people with Burning Mouth Syndrome and Oral Mucosa Disease, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 3 sites in China.
Trial summary
Burning mouth syndrome is one of the most common oral mucosal diseases in clinic. It is a chronic pain syndrome with extensive burning pain of oral mucosa as its main symptoms. There are no pathological changes in oral mucosa and no characteristic histopathological changes. Read more about this study
- Who is it for?
- Ages 25 to 90 years
- Conditions the study is for
- Burning Mouth Syndrome, Oral Mucosa Disease
- What is being tested?
- oryzanol + vitamin B2 (riboflavin) + vitamin E
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 290 participants
- Where
- 3 sitesChina
- Study dates
- 27 Jul 2020to 1 May 2022
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Persons aged 25-90;
- By inquiring the medical history in detail, BMS can be diagnosed if the clinical symptoms and signs do not conform to the clinical characteristics, and the medical history is more than 4 months.
- Burning pain and/or dry mouth in tongue or other parts of oral mucosa were the main clinical symptoms.
- Those with normal blood routine, blood sugar, liver and kidney function, urine routine, abdominal ultrasonography, chest X-ray and other basic physical examination items;
- Those who voluntarily participate in the experiment and sign the informed consent.
Who cannot join
- There are local stimulating factors that can cause burning pain in the mouth;
- Patients with other serious oral mucosal diseases;
- Complicated with serious systemic diseases;
- Patients with mental disorders who take drugs routinely;
- Abnormal levels of sex hormones;
- Sjogren's syndrome.
Show all 11Show fewer
- Possible drug-related xerostomia.
- Pregnant or lactating women;
- The patients'cognitive level was low and they could not understand and fill in the questionnaire correctly.
- Those who fail to comply with the doctor's advice or return to the doctor on time;
- Those who participated in clinical trials within 3 months.
Trial locations and contacts
3 sites in 1 country.
China3 sites, 3 recruiting
- Not yet recruiting
Guiyang Hospital of Stomatology
Guiyang, Guizhou, 550002
Hong Zhang, 41899798@qq.com
- Not yet recruiting
Zhejiang Provincal Hospital of TCM
Hangzhou, Zhejiang, 310003
Hao Huang, dr.huangh@163.com
- Recruiting
Department of Oral Medicine, the Second Affiliated Hospital, School of Medicine Zhejiang University
Hangzhou, Zhejiang, 310009
Weilian Sun
About this study
Official title: Head Yuanshi Dian Therapy in the Treatment of Burning Mouth Syndrome: a Randomized Controlled Trial
Burning mouth syndrome is one of the most common oral mucosal diseases in clinic. It is a chronic pain syndrome with extensive burning pain of oral mucosa as its main symptoms. There are no pathological changes in oral mucosa and no characteristic histopathological changes. Patients often have accompanying symptoms such as depression and xerostomia. Although the patient does not have obvious oral lesions, the pain symptoms are more serious and the mental pressure is greater.
BMS, as a complex clinical syndrome associated with multiple factors, mainly occurs in people aged 27-87, with an average age of 61. BMS is rare among people under 30 years old. BMS is predominant in women, the ratio of male to female is 1:5 to 1:7, the incidence is 0.7%-15%, and increases with age. Up to 90% of female patients are in perimenopausal period. Symptoms occur from 3 years before menopause to 12 years after menopause.
Read more
The causes of BMS are complex, and the treatment is difficult, easy to relapse and protracted. Studies have confirmed that the occurrence and development of BMS are directly related to mental factors. Therefore, psychosocial factors are the most important pathogenic factors of BMS. If we intervene in these factors, it is hopeful to improve the curative effect of BMS.
Traditional psychotherapy methods include drug treatment, psychotherapy, surgical treatment, traditional Chinese medicine treatment, etc. Drug treatment is mainly based on different types of mental and psychological diseases, choose different pharmacological effects of drugs, so as to effectively control the disease. However, these drugs are prone to adverse reactions such as sleepiness, weight gain, headache, physical weakness, etc. The basic principle of psychotherapy is to let patients fully expose symptoms, listen to their complaints patiently, carry out explanatory psychotherapy according to their medical history or take other psychological training, so as to relieve patients' mental stress and alleviate symptoms. But this method has a long course of treatment and needs the cooperation of the patients' family members; the basic principle of surgical treatment is to resect the corresponding areas of the brain or adopt endoscopy and micro-current to treat them, but the risks and injuries caused by the operation are greater, and the adverse reactions after the operation are larger; the treatment of traditional Chinese medicine needs a long course of treatment, and the treatment of some patients. The effect is not stable enough.
The causes of BMS are complex, there is no objective disease in clinic, and the patients suffer from abnormal pain, but the treatment methods are not uniform, and the curative effect is not good, which makes the patients unable to get effective treatment in the early stage of the disease, and easy to relapse, resulting in the aggravation and development of BMS into intractable sensory abnormalities, and protracted! Literature reports confirm that the tri-drug of oryzanol-riboflavin-vitamin E (oryzanol-riboflavin-vitamin E) is a classic treatment for BMS and has been included in the classic book in China, Pharmacotherapy for oral mucosal disease . However, its long-term clinical application has found that its efficacy is unstable, and clinical symptoms after drug withdrawal. The symptoms are prone to recurrence or even aggravation. Therefore, it is necessary to use the classical program on the basis of a combination of interventions to promote the efficacy of stable and safe.
Over the past two years, the investigators has treated nearly 100 cases of BMS with head yuanshi dian therapy, and achieved satisfactory results. It can obviously relieve burning pain of BMS oral mucosa, promote saliva secretion, improve dry mouth and bitter mouth, and improve sleep to a certain extent. However, due to the limited number of cases treated, the classification of BMS is not meticulous enough, and there are still vague areas in the classification of BMS, which affects the rigorous evaluation of the therapeutic effect of BMS.
Therefore, the investigators propose a hypothesis: can the head yuanshi dian therapy be used as the main adjuvant therapy for BMS? By consulting Pubmed, OVID, CNKI, Wanfang and other major databases at home and abroad, the investigators found that there is no relevant report at home and abroad. In view of this, the investigators intend to design this randomized positive controlled clinical trial, using conventional valley-nucleus-E triple drug therapy as the positive control group, to observe the efficacy and safety of head yuanshi dian therapy for BMS, in order to find a safe and effective green non-invasive therapy, effectively alleviate or eliminate oral mucosal pain, dry mouth, etc.
Read the detailed description
2.1 Test Target
To observe the efficacy and safety of head yuanshi dian therapy in the treatment of BMS.
2.2 Case Collection 2.2.1 Diagnostic criteria
- Burning-like neuropathic pain occurs in the tongue or other parts of oral mucosa, which may be relieved or disappeared when attention is transferred.
- Most of them are accompanied by dry mouth, numbness, taste disorder, depression, insomnia and other emotional changes, neuropathological changes;
- Symptom changes may have special regularities and rhythms, such as mild morning symptoms and worsening afternoon symptoms; pain does not increase when eating or drinking water, and usually does not affect sleep; or persistent pain; or intermittent throughout the day;
2.2.3 Exclusion criteria
- There are local stimulating factors that can cause burning pain in the mouth (including bad prosthesis, sharp cusp or ridge, complete denture, etc.).
- Patients with other serious oral mucosal diseases (including bullous diseases, allergic diseases, oral candidiasis, oral lichen planus, recurrent aphthous ulcer, etc.);
2.2.4 Standards and procedures for discontinuation of trial/trial therapy When the following occurs, the trial can be stopped according to the judgement of the researcher, and the reasons for the discontinuation of the trial can be recorded in the case report form (CRF) and the original record. If the cause of adverse events leads to the discontinuation of the test, the relevant treatment should be carried out according to the adverse events.
- Misacceptance was found after enrollment;
- Those who received neurological, psychiatric drugs or other interventions during the trial;
- Those who did not use the test drug according to the doctor's advice or who were treated by the combination of internal and external heat source and push of the original point after admission into the group;
2.3 randomization In this study, multi-center (Zhejiang University Second Hospital, Zhejiang Hospital of Traditional Chinese Medicine, Guiyang Hospital of Stomatology, Guizhou, 3 clinical research centers), non-inferior effect, 1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.
2.4 Measures to Reduce and Avoid Bias In order to reduce and avoid the bias of experimental conditions, the investigators should strictly group according to the random number of groups, and adopt the corresponding treatment plan. At the same time, in order to ensure the objectivity of the study group's evaluation of cases dropped and excluded, it is necessary to clarify the statistical treatment methods and evaluation criteria for cases dropped and excluded in the statistical analysis plan.
2.5 Sample size calculation Referring to the previous study of this group, the difference and standard deviation of the mean between the two groups before treatment and after one month of treatment were used to calculate the sample size required for this study. Based on the visual analogue scale (VAS), the non-inferior boundary value was allowed to be 1 and the standard deviation was 2.3, and 113 persons were needed for each group (90% of the test efficiency and 0.025 of the alpha). Taking into account the possibility of abscission, 290 cases were finally included.
2.6 Researcher and patient training The main researcher receives relevant training in head yuanshi dian therapy, and can master the principle of the therapy and related matters needing attention, as well as the use of various psychological dosimeters. In addition, the main researcher trained the patients in this therapy so that they could take care of themselves at home.
2.7 Basic information of subjects During the first and second visits, the investigators recorded the basic information of the subjects in the BMS Case Report Form: case number, random number, visiting date, name, sex, age, occupation, employment status, education level, contact mode, nationality, communication address, systemic disease, allergy history, medication history, and so on. Family history, female subjects recorded menstrual history, routine physical examination results, etc.
2.8 Trial Groups and Treatment Programs 2.8.1 Treatment plan of control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
2.8.2 Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
2.8.3 Specific operating procedure of head yuanshi dian therapy
2.9 Evaluation Index of Therapeutic Effect After the first visit or passing the push maneuver retraining, participants will have a visit twice a week. The aim is to observe the efficacy and safety of the treatment. At the end of one week, two weeks, three weeks and one month of treatment, the researchers recorded the efficacy indicators of the patients. The immunoglobulin, hemorheology index, blood routine, ESR, CRP, blood lipid routine and changes were examined at the first diagnosis and at the end of treatment. At the end of the treatment, the drug was stopped, and the head Yuanshi Dian therapy was suspended in the experimental group. The patients were followed up one month after the treatment and three or six months after the treatment by telephone to observe the recurrence.
2.10 Blind Assessment Each of the three centers has a researcher responsible for the treatment and interpretation of the subjects. The head of the research center trained the researcher to unify the standards. Three researchers were not involved in the evaluation of efficacy. Another researcher was responsible for recording pain and emotional nature and degree score, pain index, pain multi-dimensional characteristics score, depression index, Pittsburgh sleep quality index, Kupperman menopause score, dry mouth subjective symptoms questionnaire, saliva flow, and recording laboratory results, and collecting records. Data, analysis of efficacy, the researchers do not know the specific grouping, in order to minimize the subjective impact of the researchers on the test results.
2.11 Safety Evaluation Index 2.11.1 Laboratory Indicators Two groups of subjects were required to provide the following examination reports within 12 months: blood routine, blood sugar, liver and kidney function, urine routine, abdominal ultrasonography, chest X-ray, sex hormone levels.
2.11.2 Indicators of vital signs Including blood pressure and pulse. 2.11.3 Adverse reactions The subjects in the experimental group can inform the researchers of any discomfort and have the right to withdraw from the trial at any time when they are given the head yuanshi dian therapy. When the subjects in the control group were re-visited, the researchers asked if there were any adverse reactions during the medication process. If so, they should record in detail, including the number of adverse reactions (incidence), specific reactions, elimination and so on.
- Conditions
- Burning Mouth Syndrome, Oral Mucosa Disease
- Being tested
- oryzanol + vitamin B2 (riboflavin) + vitamin E
- Keywords
- Burning Mouth Syndrome, Effect and Safety, Primary Point Push
- Medical subject headings
- Burning Mouth Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
oryzanol + vitamin B2 (riboflavin) + vitamin EDrug
Also called head yuanshi dian therapy
1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
2.Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
| Study group | Role | What they receive |
|---|---|---|
| experimental group | Experimental | On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment. Receives: Drug: oryzanol + vitamin B2 (riboflavin) + vitamin E |
| control group | Active comparator | oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment. Receives: Drug: oryzanol + vitamin B2 (riboflavin) + vitamin E |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain index
The basic method is to use a swimming scale about 10 cm long, with 10 scales on one side, and the two ends are "0" and "10" ends respectively. 0 indicates no pain and 10 points represents the most severe pain that is unbearable.
Measured: one year
Depressive mood index
Measured: one year
Pittsburgh sleep quality index
Measured: one year
Kupperman Climacteric Score
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2020
- Study start27 Jul 2020
- Primary completion1 Feb 2022 (estimated)
- Study completion1 May 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Burning Mouth SyndromeStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital, Zhejiang University, School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 290 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology
- Responsible party
- Sponsor
- Investigators
- Weilian Sun, Principal investigator, Second Affiliated Hospital, Zhejiang University, School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04481841
- Sponsor's protocol ID
- 2019-281
- Status last verified
- Jan 2021
- First submitted
- 15 Nov 2019
- Last updated
- 19 Jul 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Head Yuanshi Dian Therapy in the Treatment of Burning Mouth Syndrome: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04481841
- Acronym / sponsor ID
- 2019-281
- Conditions
- Burning Mouth Syndrome, Oral Mucosa Disease
- Keywords
- Burning Mouth Syndrome, Effect and Safety, Primary Point Push
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 290 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineUniversity, hospital or other
- Collaborators
- Zhejiang Provincial Hospital of TCM, Guiyang Hospital of Stomatology
- Study start
- 27 Jul 2020 (actual)
- Primary completion
- 1 Feb 2022 (estimated)
- Study completion
- 1 May 2022 (estimated)
- First posted
- 22 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Burning mouth syndrome is one of the most common oral mucosal diseases in clinic. It is a chronic pain syndrome with extensive burning pain of oral mucosa as its main symptoms. There are no pathological changes in oral mucosa and no characteristic histopathological changes. Patients often have accompanying symptoms such as depression and xerostomia. Although the patient does not have obvious oral lesions, the pain symptoms are more serious and the mental pressure is greater.
BMS, as a complex clinical syndrome associated with multiple factors, mainly occurs in people aged 27-87, with an average age of 61. BMS is rare among people under 30 years old. BMS is predominant in women, the ratio of male to female is 1:5 to 1:7, the incidence is 0.7%-15%, and increases with age. Up to 90% of female patients are in perimenopausal period. Symptoms occur from 3 years before menopause to 12 years after menopause.
The causes of BMS are complex, and the treatment is difficult, easy to relapse and protracted. Studies have confirmed that the occurrence and development of BMS are directly related to mental factors. Therefore, psychosocial factors are the most important pathogenic factors of BMS. If we intervene in these factors, it is hopeful to improve the curative effect of BMS.
Traditional psychotherapy methods include drug treatment, psychotherapy, surgical treatment, traditional Chinese medicine treatment, etc. Drug treatment is mainly based on different types of mental and psychological diseases, choose different pharmacological effects of drugs, so as to effectively control the disease. However, these drugs are prone to adverse reactions such as sleepiness, weight gain, headache, physical weakness, etc. The basic principle of psychotherapy is to let patients fully expose symptoms, listen to their complaints patiently, carry out explanatory psychotherapy according to their medical history or take other psychological training, so as to relieve patients' mental stress and alleviate symptoms. But this method has a long course of treatment and needs the cooperation of the patients' family members; the basic principle of surgical treatment is to resect the corresponding areas of the brain or adopt endoscopy and micro-current to treat them, but the risks and injuries caused by the operation are greater, and the adverse reactions after the operation are larger; the treatment of traditional Chinese medicine needs a long course of treatment, and the treatment of some patients. The effect is not stable enough.
The causes of BMS are complex, there is no objective disease in clinic, and the patients suffer from abnormal pain, but the treatment methods are not uniform, and the curative effect is not good, which makes the patients unable to get effective treatment in the early stage of the disease, and easy to relapse, resulting in the aggravation and development of BMS into intractable sensory abnormalities, and protracted! Literature reports confirm that the tri-drug of oryzanol-riboflavin-vitamin E (oryzanol-riboflavin-vitamin E) is a classic treatment for BMS and has been included in the classic book in China, Pharmacotherapy for oral mucosal disease . However, its long-term clinical application has found that its efficacy is unstable, and clinical symptoms after drug withdrawal. The symptoms are prone to recurrence or even aggravation. Therefore, it is necessary to use the classical program on the basis of a combination of interventions to promote the efficacy of stable and safe.
Over the past two years, the investigators has treated nearly 100 cases of BMS with head yuanshi dian therapy, and achieved satisfactory results. It can obviously relieve burning pain of BMS oral mucosa, promote saliva secretion, improve dry mouth and bitter mouth, and improve sleep to a certain extent. However, due to the limited number of cases treated, the classification of BMS is not meticulous enough, and there are still vague areas in the classification of BMS, which affects the rigorous evaluation of the therapeutic effect of BMS.
Therefore, the investigators propose a hypothesis: can the head yuanshi dian therapy be used as the main adjuvant therapy for BMS? By consulting Pubmed, OVID, CNKI, Wanfang and other major databases at home and abroad, the investigators found that there is no relevant report at home and abroad. In view of this, the investigators intend to design this randomized positive controlled clinical trial, using conventional valley-nucleus-E triple drug therapy as the positive control group, to observe the efficacy and safety of head yuanshi dian therapy for BMS, in order to find a safe and effective green non-invasive therapy, effectively alleviate or eliminate oral mucosal pain, dry mouth, etc.
Detailed description
2.1 Test Target
To observe the efficacy and safety of head yuanshi dian therapy in the treatment of BMS.
2.2 Case Collection 2.2.1 Diagnostic criteria
- Burning-like neuropathic pain occurs in the tongue or other parts of oral mucosa, which may be relieved or disappeared when attention is transferred.
- Most of them are accompanied by dry mouth, numbness, taste disorder, depression, insomnia and other emotional changes, neuropathological changes;
- Symptom changes may have special regularities and rhythms, such as mild morning symptoms and worsening afternoon symptoms; pain does not increase when eating or drinking water, and usually does not affect sleep; or persistent pain; or intermittent throughout the day;
2.2.3 Exclusion criteria
- There are local stimulating factors that can cause burning pain in the mouth (including bad prosthesis, sharp cusp or ridge, complete denture, etc.).
- Patients with other serious oral mucosal diseases (including bullous diseases, allergic diseases, oral candidiasis, oral lichen planus, recurrent aphthous ulcer, etc.);
2.2.4 Standards and procedures for discontinuation of trial/trial therapy When the following occurs, the trial can be stopped according to the judgement of the researcher, and the reasons for the discontinuation of the trial can be recorded in the case report form (CRF) and the original record. If the cause of adverse events leads to the discontinuation of the test, the relevant treatment should be carried out according to the adverse events.
- Misacceptance was found after enrollment;
- Those who received neurological, psychiatric drugs or other interventions during the trial;
- Those who did not use the test drug according to the doctor's advice or who were treated by the combination of internal and external heat source and push of the original point after admission into the group;
2.3 randomization In this study, multi-center (Zhejiang University Second Hospital, Zhejiang Hospital of Traditional Chinese Medicine, Guiyang Hospital of Stomatology, Guizhou, 3 clinical research centers), non-inferior effect, 1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.
2.4 Measures to Reduce and Avoid Bias In order to reduce and avoid the bias of experimental conditions, the investigators should strictly group according to the random number of groups, and adopt the corresponding treatment plan. At the same time, in order to ensure the objectivity of the study group's evaluation of cases dropped and excluded, it is necessary to clarify the statistical treatment methods and evaluation criteria for cases dropped and excluded in the statistical analysis plan.
2.5 Sample size calculation Referring to the previous study of this group, the difference and standard deviation of the mean between the two groups before treatment and after one month of treatment were used to calculate the sample size required for this study. Based on the visual analogue scale (VAS), the non-inferior boundary value was allowed to be 1 and the standard deviation was 2.3, and 113 persons were needed for each group (90% of the test efficiency and 0.025 of the alpha). Taking into account the possibility of abscission, 290 cases were finally included.
2.6 Researcher and patient training The main researcher receives relevant training in head yuanshi dian therapy, and can master the principle of the therapy and related matters needing attention, as well as the use of various psychological dosimeters. In addition, the main researcher trained the patients in this therapy so that they could take care of themselves at home.
2.7 Basic information of subjects During the first and second visits, the investigators recorded the basic information of the subjects in the BMS Case Report Form: case number, random number, visiting date, name, sex, age, occupation, employment status, education level, contact mode, nationality, communication address, systemic disease, allergy history, medication history, and so on. Family history, female subjects recorded menstrual history, routine physical examination results, etc.
2.8 Trial Groups and Treatment Programs 2.8.1 Treatment plan of control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
2.8.2 Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.
2.8.3 Specific operating procedure of head yuanshi dian therapy
2.9 Evaluation Index of Therapeutic Effect After the first visit or passing the push maneuver retraining, participants will have a visit twice a week. The aim is to observe the efficacy and safety of the treatment. At the end of one week, two weeks, three weeks and one month of treatment, the researchers recorded the efficacy indicators of the patients. The immunoglobulin, hemorheology index, blood routine, ESR, CRP, blood lipid routine and changes were examined at the first diagnosis and at the end of treatment. At the end of the treatment, the drug was stopped, and the head Yuanshi Dian therapy was suspended in the experimental group. The patients were followed up one month after the treatment and three or six months after the treatment by telephone to observe the recurrence.
2.10 Blind Assessment Each of the three centers has a researcher responsible for the treatment and interpretation of the subjects. The head of the research center trained the researcher to unify the standards. Three researchers were not involved in the evaluation of efficacy. Another researcher was responsible for recording pain and emotional nature and degree score, pain index, pain multi-dimensional characteristics score, depression index, Pittsburgh sleep quality index, Kupperman menopause score, dry mouth subjective symptoms questionnaire, saliva flow, and recording laboratory results, and collecting records. Data, analysis of efficacy, the researchers do not know the specific grouping, in order to minimize the subjective impact of the researchers on the test results.
2.11 Safety Evaluation Index 2.11.1 Laboratory Indicators Two groups of subjects were required to provide the following examination reports within 12 months: blood routine, blood sugar, liver and kidney function, urine routine, abdominal ultrasonography, chest X-ray, sex hormone levels.
2.11.2 Indicators of vital signs Including blood pressure and pulse. 2.11.3 Adverse reactions The subjects in the experimental group can inform the researchers of any discomfort and have the right to withdraw from the trial at any time when they are given the head yuanshi dian therapy. When the subjects in the control group were re-visited, the researchers asked if there were any adverse reactions during the medication process. If so, they should record in detail, including the number of adverse reactions (incidence), specific reactions, elimination and so on.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- 1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.
| Arm | Type | Receives |
|---|---|---|
| experimental group | Experimental | Drug: oryzanol + vitamin B2 (riboflavin) + vitamin EOn the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment. |
| control group | Active comparator | Drug: oryzanol + vitamin B2 (riboflavin) + vitamin Eoryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment. |
Who may qualify
- Ages
- 25 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Persons aged 25-90;
- By inquiring the medical history in detail, BMS can be diagnosed if the clinical symptoms and signs do not conform to the clinical characteristics, and the medical history is more than 4 months.
- Burning pain and/or dry mouth in tongue or other parts of oral mucosa were the main clinical symptoms.
- Those with normal blood routine, blood sugar, liver and kidney function, urine routine, abdominal ultrasonography, chest X-ray and other basic physical examination items;
- Those who voluntarily participate in the experiment and sign the informed consent.
Key exclusion criteria (11 listed)
- There are local stimulating factors that can cause burning pain in the mouth;
- Patients with other serious oral mucosal diseases;
- Complicated with serious systemic diseases;
- Patients with mental disorders who take drugs routinely;
- Abnormal levels of sex hormones;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| oryzanol + vitamin B2 (riboflavin) + vitamin EAlso: head yuanshi dian therapy1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment. 2.Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment. | Drug | control group, experimental group |
Primary outcome
Pain index
Time frame: one year
The basic method is to use a swimming scale about 10 cm long, with 10 scales on one side, and the two ends are "0" and "10" ends respectively. 0 indicates no pain and 10 points represents the most severe pain that is unbearable.
Depressive mood index
Time frame: one year
Pittsburgh sleep quality index
Time frame: one year
Kupperman Climacteric Score
Time frame: one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2021.
- Individual participant dataSharing planned: No
Related trials for Burning Mouth Syndrome
Not yet recruiting
Improving Prescribing Quality for Oral Mucosal Disorders Using a Pharmacist-Led Model
Oral Lichen Planus, Recurrent Aphthous Stomatitis
Recruiting
MucoLock™ for Treatment of Stomatitis
Stomatitis, Pain
RecruitingObservational study
Reducing Patient Memory Recall in the Burning Mouth Patient Population
Burning Mouth Syndrome
Active, not recruiting
Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment
Burning Mouth Syndrome, Low Level Laser Therapy
Not yet recruiting
Burning Mouth Syndrome: Effects of Occlusal Splint Therapy
Burning Mouth Syndrome, Orofacial Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Weilian Sun principal investigator
Second Affiliated Hospital, Zhejiang University, School of Medicine
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing oryzanol + vitamin B2 (riboflavin) + vitamin E in people with Burning Mouth Syndrome and Oral Mucosa Disease, run by Second Affiliated Hospital, Zhejiang University, School of Medicine at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Weilian Sun, PhD (13757119563, weiliansun@zju.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain index (time frame: one year). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2021.